230 filings
Page 2 of 12
6-K
fr4z69
18 Apr 23
Current report (foreign)
8:05am
UPLOAD
s2v8s0t
4 Apr 23
Letter from SEC
12:00am
RW
uowwdo1i
29 Mar 23
Registration withdrawal request
4:54pm
F-3
k545xr
29 Mar 23
Shelf registration (foreign)
4:53pm
6-K
vgscrnvhee9mg6mer11
29 Mar 23
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
8:07am
6-K
rnxwr23
10 Mar 23
Current report (foreign)
4:10pm
6-K
25x4k1qtgrsc8g q537
23 Dec 22
Current report (foreign)
7:10am
6-K
b3gdpscq
9 Nov 22
Current report (foreign)
7:03am
6-K
juv05wgnp8ahj7dt9
21 Sep 22
Current report (foreign)
4:16pm
6-K
aq56uq2z3x
11 Aug 22
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
7:33am
6-K
hz5qzi
4 Aug 22
Current report (foreign)
7:18am
6-K
1jylvdu20mj3j0y 33
30 Jun 22
Current report (foreign)
4:32pm
6-K
a4tsp2ng
1 Jun 22
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
7:05am
6-K
f73dkwb6348h2siyu3
5 May 22
Current report (foreign)
12:00am
6-K
o3wmcg jnu8bnpwe95s6
13 Apr 22
Current report (foreign)
8:02am
6-K
sgg85whv 64
13 Apr 22
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
7:09am
424B5
36zihy jcwkqwwg
10 Mar 22
Prospectus supplement for primary offering
8:55am
EFFECT
7qu1tvkprlu
10 Mar 22
Notice of effectiveness
12:15am